Gland Pharma · NSE: GLAND · BSE: 543245
Q2 FY25 results · Jul–Sep 2024
Gland Pharma reported revenue from operations of ₹1,405.83 crore (up 2.4% from Q2 FY24) and net profit of ₹163.53 crore (down 15.7% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,405.83 | 1,373.42 | +2.4% | 1,401.71 | +0.3% |
| Other income | 59.66 | 53.16 | +12.2% | 51.43 | +16.0% |
| Total income | 1,465.49 | 1,426.58 | +2.7% | 1,453.14 | +0.9% |
| Profit before tax | 256.78 | 289.89 | −11.4% | 218.25 | +17.7% |
| Net profit for the period | 163.53 | 194.08 | −15.7% | 143.76 | +13.8% |
| EPS, basic (₹) | 9.93 | 11.78 | −15.7% | 8.73 | +13.7% |
| Net margin (%) | 11.6 | 14.1 | 10.3 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,062.99 | 1,010.67 | +5.2% | 1,012.02 | +5.0% |
| Other income | 57.80 | 41.11 | +40.6% | 48.49 | +19.2% |
| Total income | 1,120.79 | 1,051.78 | +6.6% | 1,060.51 | +5.7% |
| Profit before tax | 379.82 | 347.06 | +9.4% | 300.31 | +26.5% |
| Net profit for the period | 281.71 | 257.53 | +9.4% | 222.92 | +26.4% |
| EPS, basic (₹) | 17.10 | 15.64 | +9.3% | 13.53 | +26.4% |
| Net margin (%) | 26.5 | 25.5 | 22.0 |
Consolidated
- Filed with BSE
- 04 Nov 2024, 18:20 IST
- Board meeting
- 04 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 Nov 2024, 18:20 IST
- Board meeting
- 04 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE